Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.
Louise LindeStylianos GeorgiadisLykke M ØrnbjergSimon H RasmussenBrigitte MichelsenJohan AsklingDaniela Di GiuseppeJohan Karlsson WallmanJakub ZávadaKarel PavelkaMiguel BernardesCarolina O MatosBente GlintborgAnne Gitte LoftDan NordströmLaura KuusaloBurkhard MöllerMichael J NissenCatalin CodreanuCorina MogosanBjorn GudbjornssonThorvardur Jon LoveCansu AkleylekFlorenzo IannoneTore K KvienZiga RotarIsabel CastrejonGary John MacfarlaneMerete L HetlandMikkel ØstergaardPublished in: Arthritis care & research (2024)
In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.